⋒ FACULTY OF U PHARMACEUTICAL SCIENCES

DRUQUAR



Characterisation of magnesium ascorbyl phosphate, a raw material in cell therapy


<u>Xiaolong Xu¹, Magdalena Woźniczka², Toon Verstraelen³, Kristof Van Hecke³, Patrick Bultinck³, Carl Mensch^{3,4}, Dieter Buyst⁵,</u> Eric Deconinck⁶, Evelien Wynendaele¹, Karen Herman¹ and Bart De Spiegeleer^{1*}

¹Drug Quality and Registration (DruQuaR) group, Faculty of Pharmaceutical Sciences; ³Department of Chemistry; ⁵Department of Organic and Macromolecular Chemistry; all Ghent University. ²Faculty of Pharmacy, Medical University of Łódź; ⁴Department of Chemistry, University of Antwerp; ⁶Section of Medicines & Health Care Products, Scientific Direction Chemical & Physical Health Risks, Sciensano.

*Corresponding author: bart.despiegeleer@UGent.be

our reference:2018-224b





Advanced therapy medicinal products (ATMPs), encompassing gene, cell and tissue engineering medicinal products, offer completely new perspectives for the treatment of severe diseases. However, the development of this new class of medicines is challenging, *i.a.* due to appropriate quality specification for the raw materials used during their manufacturing. Magnesium ascorbyl phosphate (APMg), with superior biological effects compared to ascorbic acid or sodium ascorbyl phosphate, is frequently used in cell culture as well as in the manufacturing of ATMPs.

PROBLEM: ANALYTICAL-CHEMICAL CHARACTERISATION?


EXPERIMENTAL

> Stoichiometric composition: magnesium assay by titration and atomic absorption spectroscopy (AAS), ligand assay by HILIC-HPLC, residual solvent by GC, water content by loss on drying (LOD) and thermogravimetric analysis (TGA)

- Impurity profiling: HILIC-HPLC coupled to LC-MS/MS and high resolution mass (HRMS)
- > Aqueous structure investigation: the APMg structure was studied using potentiometric titration at different ligand-to-magnesium molar ratios

RESULTS and DISCUSSION

1. Stoichiometric composition (2 CAS numbers: Mg/Ligand=3/2 and 1/1)



8 batches of APMg obtained from the market were analyzed using different techniques.

1) Solvent: a) residual organic solvent: < RT (GC) b) water: LOD: 5.8-21.8%

TGA: 12.7-22.5% FT-IR→TGA residue at 200°C: APMg remains intact TGA residue at 400°C: APMg degraded

2) Mg content:

a) AAS: 8.9-10.0% b) Titration: 9.2-10.1%


3) Ligand content (HILIC-HPLC): 61.0-75.5%

 $(AP)_2Mg_3 \cdot n H_2O(n:2-5)$

2. Impurity identification

0.60 0.55 0.50	APMg batch 75380	АРМ
0.45		
0.40		
0.35		
₹ 0.30		

MP: 15 mM **KH**₂**PO**₄ **buffer** (pH 2.5 with HCI): acetonitrile (30:70, v/v)SP: Obelisc N column (3.2 × 150 mm, 5 μ m) – 25°C



- > APMg: different CAS number but stoichiometry inconsistent
- \succ Different impurity profile: three unknown impurities identified as the ethylation products of APMg
- \succ In the physiological condition: Mg₃(AP)₂ complex as main structure in solution

REFERENCES

> Xiaolong Xu, Serge Van Calenbergh, Magdalena Woźniczka, Evelien Wynendaele, Karen Herman, Bart De Spiegeleer. Zwitterionic-hydrophilic interaction liquid chromatography for L-ascorbic acid 2-phosphate magnesium, a raw material in cell therapy. Manuscript submitted (2018).

> Xiaolong Xu, Magdalena Woźniczka, Toon Verstraelen, Kristof Van Hecke, Patrick Bultinck, Christian Johannessen, Carl Mensch, Dimitrije Mara, Karen Herman, Evelien Wynendaele, Eric Deconinck, Bart De Spiegeleer. Solution structure of hydrated L-ascorbate 2-phosphate magnesium as a raw material in cell and tissue therapy. Manuscript in preparation, 2018. Acknowledgement: China Scholarship Council (CSC)